Mark Reed

Dr. Reed is a medicinal chemist and Staff Scientist at the Krembil, University Health Network (UHN). In 2018, Dr. Reed established the Centre for Medicinal Chemistry and Drug Discovery (CMCDD) to help academic researchers translate their discoveries into druggable targets. The facility offers medicinal chemistry support such as probe synthesis, hit identification strategies, hit to lead/ lead optimization, molecular modelling and Intellectual property. The goal is to work harmoniously with the researchers to develop a road map for the discovery and development of small molecule therapeutics that can be commercialized into meaningful treatments for disease.

Dr. Reed has over 20 years of industrial experience in drug discovery, working in startups (Treventis Corporation, Toronto), biotech (ICOS corporation, Seattle) and large pharma (Schering Plough Research Institute, Cambridge, MA). Dr. Reed has implemented modern medicinal chemistry practices to identify and advance de-risked lead compounds towards the clinic in the areas of CNS, anti-infectives, immunology and oncology.  Dr. Reed has published multiple papers and patents in areas of synthetic organic chemistry, neurodegeneration, neuropathic pain and inflammation.

Dr. Reed is cross appointed with the Department of Chemistry and the Department of Pharmacology and Toxicology.